Google article title if interested, "Gasp! There's a worldwide wine shortage"
"Morgan Stanley Research show a shortage last year of nearly 300 million cases with the problem only getting worse."
Google tile/subject if interested in complete article.
"It seems the problem is we’re all drinking too much vino, at least in the United States and China.
Statistics put together by Morgan Stanley Research show a shortage last year of nearly 300 million cases with the problem only getting worse.
Quartz reports lower production teamed with extra demand will make this year’s crisis, already the worst in 50 years, even worse."
Just the beginning, as the revenue role in, and it WILL, we go much higher. $18 - $22 is a better number and will not be long before we start seeing upgrades with price targets that head there.
GLTA (Longs that is) :-)
Your only considering the ending variable, and need to consider the starting, or entry variable. One shouldn't come to the party late and expect all the food to still be available :-) That being said, I have buys in SSH in the $3's
"Nearly two out of every three acetaminophen overdoses are attributed to hydrocodone-acetaminophen products."
“A significant proportion of patients on existing forms of immediate-release hydrocodone-acetaminophen combination treatments have liver disease or risk factors, and the availability of an acetaminophen-free formulation encompassing a range of hydrocodone doses is an important therapeutic option for these patients.”
Go to their website, look under PIPELINE and you can READ this words. No dilution, just a nice POSITIVE partner announcement coming.
Removal of Acetaminophen is their differentiator. FDA is VERY aware of, and concerned about, the issues related to Acetaminophen. The 11-2 panel vote was an example of logic losing to politics. Powers that be understand there is true BENEFIT (less harm) for many patients. Hydrocodone is on the market, and presently needs to be, until we get 181. This version/option just makes it less damaging for many.
"Zohydro ER is the first extended-release formulation hydrocodone therapy without acetaminophen. The use of products containing acetaminophen in high doses over long periods of time has the potential for causing liver injury."
When we see another 13G we will know, or could be many someone's. Volume has been up, the new facilities should draw lots of press in 2014, so that should help to bring evenire buyers.
Nah, I'm significantly invested in both. Different patient populations, and the unfortunate reality is lots of patients for both. :-(
Yup, I remember you did, and expecting they will be. I'm good with current core position, but want to see Wednesday, especially with Washington & Mr. Market's behavior of late. Never know when one or the other will offer up a real sale. Expecting to add Wednesday. Will pay more, but like you, i believe we go significantly higher, long term. THOR is a winner.
Wednesdays the big day. Still looking to add to my core position, and pick up trading shares, but with all the noise in Washington, and WEDNESDAY on the horizon, have been just watching us drift up. Decisions, decisions.....Think I'll have another glass of WVVI. :-)
Couple additional points for same article
1) "According to the Centers for Disease Control and Prevention, more than 16,500 people died after overdosing on opioid-based painkillers in 2010, the last year for which data are available.
!!!!!!!! No other class of drugs, legal or illegal, is responsible for as many deaths, its figures show.!!!!!!!!!!"
2) "Janet Woodcock, director of the FDA's center for drug evaluation, said in a statement that the agency "has become increasingly concerned about the abuse and misuse of opioid products, which have sadly reached epidemic proportions in certain parts of the United States."
She said the challenge for the agency has been to ensure that people living with severe pain also have access to needed relief.
She said the agency acted following hundreds of public comments and several public meetings, including the two-day advisory panel convened in January. The process leading to Thursday's action began in 2009, when the DEA asked the Health and Human Services Department, which includes the FDA, to recommend whether to reclassify the hydrocodone-containing products as Schedule II controlled substances."